Comprehensive analysis of genetic aberrations linked to tumorigenesis in regenerative nodules of liver cirrhosis

ConclusionAnalyses of RNs constructing cirrhotic liver indicated that a variety of genetic aberrations accumulate in the cirrhotic liver before the development of clinically and histologically overt HCC. These aberrations in RNs could provide the basis of tumorigenesis in patients with liver cirrhosis.
Source: Journal of Gastroenterology - Category: Gastroenterology Source Type: research

Related Links:

ConclusionPre-transplant performance status is one of the predictors of mortality after LDLT.
Source: Journal of Clinical and Experimental Hepatology - Category: Gastroenterology Source Type: research
This study aimed to explore an effective noninvasive approach to accurately predict post-transplant tumor recurrence.Materials and methodsMetabolomics profiling was performed on pre-operative plasma from 122 HCC patients undergoing liver transplantation, 52 healthy controls (HC) and 25 liver cirrhosis (LC) patients.ResultsFive prognostic metabolites were identified by univariate analysis (P 
Source: European Journal of Surgical Oncology (EJSO) - Category: Surgery Source Type: research
ConclusionSurvival in DC was shorter than what was expected in the natural history of the disease after GCSF use.
Source: Journal of Clinical and Experimental Hepatology - Category: Gastroenterology Source Type: research
In conclusion, our results have revealed that the lack of PTP1B switches NOX expression pattern in response to liver injury after BDL and reduces HSC activation and liver fibrosis.Graphical abstract
Source: Redox Biology - Category: Biology Source Type: research
CONCLUSIONS: Disease burden associated with chronic HCV infection is projected to peak in the Czech Republic in 30-40 years. Assuming that the current portion of DAAs used remains constant, a significant reduction in HCV disease burden is possible through increased diagnosis and treatment through 2030. This analysis provides evidence in order to facilitate the development of national strategies for HCV care and management in the Czech Republic. PMID: 31241282 [PubMed - in process]
Source: Central European Journal of Public Health - Category: International Medicine & Public Health Tags: Cent Eur J Public Health Source Type: research
Conditions:   Liver Diseases;   Liver Transplantation;   Complicated Cirrhosis of Hepatocellular Carcinoma;   Acute Decompensation of Cirrhosis;   Chronic Decompensation of Cirrhosis Intervention:   Biological: blood sample Sponsor:   Hospices Civils de Lyon Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Hepatocellular carcinoma (HCC) is the second most common cause of cancer death worldwide, with a majority of HCC patients not suitable for curative therapies. Approximately 70% of initially diagnosed patients cannot undergo surgical resection or transplantation candidates due to locally advanced disease, poor liver function/underlying cirrhosis, or additional comorbidities. Local therapeutic options for patients with unresectable HCC, not suitable for thermal ablation, include transarterial embolization (bland, chemoembolization, radioembolization) and/or external beam radiation therapy (EBRT). Regarding EBRT specifically,...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Conclusion: Our data indicate that the risk of microvascular invasion is highest in tumors localized to segment 8. The size and number of HCC tumors were not associated with an increased risk of microvascular invasion. PMID: 31186641 [PubMed]
Source: Journal of Cancer Epidemiology - Category: Epidemiology Tags: J Cancer Epidemiol Source Type: research
ConclusionSurvival in DC was shorter than what was expected in the natural history of the disease after GCSF use.
Source: Journal of Clinical and Experimental Hepatology - Category: Gastroenterology Source Type: research
AbstractNonalcoholic steatohepatitis (NASH) is a chronic, progressive disease, that can advance to fibrosis, cirrhosis, and hepatocellular carcinoma. Despite being a leading cause of liver transplantation, there are no approved pharmacological treatments. Our aim was to identify literature on management options in NASH. Our structured review of interventions treating NASH patients from English language publications between 1 January 2007 and 25 September 2017 elicited 48 eligible references. Lifestyle management was identified as the mainstay of NASH therapy. Vitamin E and pioglitazone reported reductions in steatosis; how...
Source: Pharmacology Research and Perspectives - Category: Drugs & Pharmacology Authors: Tags: REVIEW Source Type: research
More News: Cancer & Oncology | Carcinoma | Cirrhosis | Gastroenterology | Genetics | Hepatocellular Carcinoma | Liver | Liver Cancer | Liver Transplant | Molecular Biology | Transplants | Urology & Nephrology